{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-008992","form_type":"8-K","ticker":"ANTX","cik":"0001880438","company_name":"AN2 Therapeutics, Inc.","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.980630+00:00","generated_at":"2026-06-25T22:01:41.489421+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"medium","headline":"AN2 Therapeutics reports Q1 2022 results, cash $118.4M; progresses epetraborole clinical program","bullets":["Cash and investments total $118.4M as of March 31, 2022; expects operating runway through mid-2024.","Upsized IPO raised $79.4M; full exercise of underwriter option added $10.4M in April.","Phase 2/3 trial enrollment for treatment-refractory MAC lung disease expected to begin H1 2022.","FDA cleared IND, granted Fast Track, QIDP, and orphan drug designation for epetraborole.","Appointed Dr. Mel Spigelman and Maggie FitzPatrick to Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-008992","json":"https://secwatch.observer/filing/0000950170-22-008992.json","markdown":"https://secwatch.observer/filing/0000950170-22-008992.md","text":"https://secwatch.observer/filing/0000950170-22-008992.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1880438/000095017022008992/0000950170-22-008992-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1880438/000095017022008992/antx-20220510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T22:01:41.489421+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}